NCT03845010View on ClinicalTrials.gov

Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

January 17, 2023

Study Completion Date

January 17, 2023

Conditions
Ventricular Premature Beats
Interventions
DRUG

Sotalol

Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)

DRUG

Flecainide and verapamil

Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day

PROCEDURE

Catheter ablation

Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine

Trial Locations (1)

Unknown

Isala hospital, Zwolle

All Listed Sponsors
lead

Maatschap Cardiologie Zwolle

OTHER

NCT03845010 - Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment | Biotech Hunter | Biotech Hunter